SCHIZOPHRENIFORM DISORDER

This study tests whether carefully reducing antipsychotic medication in stable schizophrenia patients can improve their daily functioning compared to staying on the same dose. Researchers will group 288 adults aged 18–60 by their specific psychosis type and randomly assign them t…

This study tests whether a 45-minute session of viewing visual illusions with a partner can improve social cognition in people with psychotic disorders. Social cognition is the ability to understand what others think or feel. Sixty participants will be guided through illusion box…

This study tests a smartphone app called NST-SPARK that uses augmented reality games to help people with schizophrenia who struggle with low motivation, lack of pleasure, and social withdrawal. About 30 adults with these symptoms will use the app for 12 weeks. The goal is to see …

This study tests whether adding cannabidiol (CBD) to standard antipsychotic medication can improve symptoms in people experiencing their first episode of psychosis who haven't responded well to initial treatment. About 250 participants aged 16-40 will receive either CBD or a plac…

This study uses PET scans to see how two antipsychotic medications, brexpiprazole and cariprazine, bind to dopamine-3 receptors in the brains of people with schizophrenia. Forty participants take one of the drugs for 15 days and get brain scans before, after one day, and after 15…

This study looks at whether teaching people in the hospital about their psychiatric medications helps them stick to their treatment and handle side effects. Researchers will work with 64 adults who have serious mental illnesses like schizophrenia or bipolar disorder. The goal is …

This study investigates how insulin delivered through the nose changes dopamine signaling and energy use in the brains of people with first-episode psychosis. Researchers will compare brain scans and chemical levels in 46 participants (patients and healthy volunteers) after recei…